Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01363804 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Tivozanib in Healthy Subjects
A Phase 1 study, sponsored by AVEO Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01363804 is a Phase 1 study that has completed, run by AVEO Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT01363804, a Phase 1 study, has completed, sponsored by AVEO Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is designed to evaluate the effect of rifampin on the Pharmacokinetic (PK) profile of tivozanib.
Interventions
- DRUG Tivozanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01363804
The ClinicalTrials.gov registry entry for NCT01363804 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AVEO Pharmaceuticals, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tivozanib is the first listed.
NCT01363804 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01363804 about?
NCT01363804 is a clinical study titled "A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Tivozanib in Healthy Subjects". This study is designed to evaluate the effect of rifampin on the Pharmacokinetic (PK) profile of tivozanib.
What is the current status of trial NCT01363804?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2011-05. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01363804?
The interventions under investigation include: Tivozanib (DRUG).
Who is sponsoring clinical trial NCT01363804?
This trial is sponsored by AVEO Pharmaceuticals, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.